Cubist upgraded to Hold from Sell at Cantor Cantor upgraded Cubist to Hold citing the playing out of negative catalysts following the company's Q4 results and 2013 outlook. The firm raised its price target for shares to $38 from $37.
News For CBST From The Last 14 Days
Check below for free stories on CBST the last two weeks.
Cubist annouces EMA acceptance of ceftolozane, tazobactam MAA Cubist announced that the European Medicines Agency has accepted for review the company’s Marketing Authorization Application for its investigational antibiotic ceftolozane, tazobactam. Cubist is seeking approval of ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections, with a decision from the European Commission expected during 1H15. The MAA submission is based on positive data from two pivotal Phase 3 clinical trials of ceftolozane, tazobactam in complicated urinary tract infections and complicated intra-abdominal infections. These studies met both the EMA and U.S. Food and Drug Administration specified primary endpoints. Results of the secondary analyses were consistent with and supportive of the primary outcomes.
Cubist may receive takeover interest, Bloomberg reports Cubist Pharmaceuticals' (CBST) focus on bacterial infections could attract takeover interest, Bloomberg reports in its Real M&A column. Reference Link